| References |
|
|
Appleton I
(1997)
Non-steroidal anti-inflammatory drugs and pain.
Handbook of Experimental Pharmacology
130:
43–60.
|
|
|
Bayburt T,
Yu BZ,
Lin H et al.
(1993)
Human nonpancreatic secreted phospholipase A2: interfacial parameters, substrate specificities, and competitive inhibitors.
Biochemistry
32:
573–582.
|
|
|
Berg OG,
Gelb MH,
Tsai M-D and
Jain MK
(2001)
Interfacial enzymology: the secreted phospholipase A2-paradigm.
Chemical Reviews
101:
2613–2653.
|
|
|
Berg OG,
Rogers J,
Yu BZ et al.
(1997)
Thermodynamic and kinetic basis for interfacial activation. Resolution of binding and allosteric effects on pancreatic phospholipase A2 at zwitterionic interfaces.
Biochemistry
36:
14512–14530.
|
|
|
Bode C,
Maute G and
Bode JC
(1996)
Prostaglandin I2 and prostaglandin F2 biosynthesis in human gastric mucosa: effect of chronic alcohol misuse.
Gut
39:
348–352.
|
|
|
Borgeat P and
Naccache PH
(1990)
Biosynthesis and biological activity of leukotriene B4.
Clinical Biochemistry
23:
459–468.
|
|
|
Breyer MD
(1998)
Prostaglandin receptors in the kidney: a new route for intervention?
Experimental Nephrology
6:
180–188.
|
|
|
Burke JE and
Dennis EA
(2009)
Phospholipase A2 structure/function, mechanism, and signalling.
Journal of Lipid Research
50:
S237–S242.
|
|
|
Capdevila JH and
Falck JR
(2002)
Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases.
Prostaglandins and Other Lipid Mediators
68 and 69:
325–344.
|
|
|
Cipollone F,
Cicolini G and
Bucci M
(2008)
Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives.
Pharmacology and Therapeutics
118:
161–180.
|
|
|
Daikh BE,
Lasker JM,
Raucy JL and
Koop DR
(1994)
Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9.
Journal of Pharmacology and Experimental Therapeutic
271:
1427–1433.
|
|
|
Ford-Hutchinson AW,
Gresser M and
Young RN
(1994)
5-Lipoxygenase.
Annual Review of Biochemistry
63:
383–417.
|
|
|
Ghosh M,
Tucker DE,
Burchett SA and
Leslie CC
(2006)
Properties of the Group IV phospholipase A2 family.
Progress in Lipid Research
45:
487–510.
|
|
|
Glaser KB
(1995)
Regulation of phospholipase A2: selective inhibitors and their pharmacological potential.
Advances in Pharmacology
32:
31–66.
|
|
|
Goetzl EJ,
An S and
Smith WL
(1995)
Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases.
FASEB Journal
9:
1051–1058.
|
|
|
Habib A and
Maclouf J
(1992)
Comparison of leukotriene A4 metabolism into leukotriene C4 by human platelets and endothelial cells.
Archives of Biochemistry and Biophysics
298:
544–552.
|
|
|
Henderson WR
(1994)
The role of leukotrienes in inflammation.
Annals of Internal Medicine
121:
684–697.
|
|
|
Jain MK,
Gelb MH,
Rogers J and
Berg OG
(1995)
The kinetic basis of interfacial catalysis and activation of phospholipase A2.
Methods in Enzymology
249:
567–614.
|
|
|
Janben-Timmen U,
Tomiç I,
Specht E,
Beilecke U and
Habenicht AJR
(1994)
The arachidonic acid cascade, eicosanoids, and signal transduction.
Annals of the New York Academy of Sciences
733:
325–334.
|
|
|
Jania LA,
Chandrasekharan S,
Backlund MG et al.
(2009)
Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis.
Prostaglandins and Others Lipid Mediators
88:
73–81.
|
|
|
Kanai N,
Lu R,
Satriano JA,
Bao Y and
Wolkoff AW
(1995)
Identification and characterization of a prostaglandin transporter.
Science
268:
866–869.
|
|
|
Karara A,
Dishman E,
Falck JR and
Capdevila JH
(1991)
Endogenous Epoxyeicosatrienoyl-phospholipids.
Journal of Biological Chemistry
266:
7561–7569.
|
|
|
Kuehn HS,
Swindle EJ,
Kim M-S,
Beaven MA and
Metcalfe DD
(2008)
The phosphoinositide-3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells.
Journal of Immunology
181:
7706–7712.
|
|
|
Lambert-Langlais S,
Pointud J-C,
Lefrançois-Martinez A-M et al.
(2009)
Aldo keto reductase 1B7 and prostaglandin F2 are regulators of adrenal endocrine functions.
PLoS ONE
4:
e7309 (doi:10.1371/journal.pone.0007309).
|
|
|
Lin Y,
Wu KK and
Ruan K
(1998)
Characterization of secondary structure and membrane interaction of the putative membrane anchor domains of prostaglandin I2 synthase and cytochrome P450 2C1.
Archives of Biochemistry and Biophysics
352:
78–84.
|
|
|
Loewen PS
(2002)
Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects.
Canadian Journal of Emergency Medicine
4:
268–275.
|
|
|
Lovgren AK,
Kovarova M and
Koller BH
(2007)
cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis.
Molecular and Cellular Biology
27:
4416–4430.
|
|
|
Luo M,
Flamand N and
Brock TG
(2006)
Metabolism of arachidonic acid to eicosanoids within the nucleus.
Biochimica et Biophysica Acta
1761:
618–625.
|
|
|
Maclouf J,
Folco G and
Patrono C
(1998)
Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease.
Thrombosis and Haemostasis
79:
691–705.
|
|
|
Mancini JA,
Waugh RJ,
Thompson JA et al.
(1998)
Structural characterization of the covalent attachment of leukotriene A3 to leukotriene A4 hydrolase.
Archives of Biochemistry and Biophysics
354:
117–124.
|
|
|
other
Mbalaviele G,
Pauley AM,
Shaffer AF,
Zweifel BS and
Mathialagan S
(2010) Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cycloxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochemical Pharmacology doi: 10.1016/j.bcp.2010.01.003.
|
|
|
Murakami M,
Naraba H,
Tanioka T et al.
(2000)
Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2.
Journal of Biological Chemistry
275:
32783–32792.
|
|
|
Murthy SNP,
Chung PH,
Lin L and
Lomasney JW
(2006)
Activation of phospholipase C by free fatty acids and crosstalk with phospholipase D and phospholipase A2.
Biochemistry
45:
10987–10997.
|
|
|
Nagata N,
Fujimori K,
Okasaki I,
Oda H et al.
(2009)
De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin synthase, B trace, in the kidneys.
FEBS Journal
276:
7146–7158.
|
|
|
Nakashima K,
Ueno N,
Kamei D et al.
(2003)
Coupling between cyclooxygenases and prostaglandin F2 synthase.
Biochimica et Biophysica Acta
1633:
96–105.
|
|
|
Nasrallah R and
Hébert RL
(2005)
Prostacyclin signaling in the kidney: implications for health and disease.
American Journal of Physiology: Renal Physiology
289:
F235–F246.
|
|
|
Noguchi M,
Miyano M and
Matsumoto T
(1996)
Physicochemical characterization of ATP binding to human 5-lipoxygenase.
Lipids
31:
367–371.
|
|
|
Parker CW
(1987)
Lipid mediators produced through the lipoxygenase pathway.
Annual Review of Immunology
5:
65–84.
|
|
|
Patrono C and
FitzGerald GA
(1997)
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.
Arteriosclerosis, Thrombosis and Vascular Biology
17:
2309–2315.
|
|
|
Pirich C,
Efthimiov Y,
O'Grady J and
Sinzinger H
(1997)
Hyperalphalipoproteinemia and prostaglandin I2 stability.
Thrombosis Research
88:
41–49.
|
|
|
Pozzi A,
Macias-Perez I,
Abair T et al.
(2005)
Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids.
Journal of Biological Chemistry
280:
27138–27146.
|
|
|
Ragolia L,
Palaia T,
Hall CE et al.
(2005)
Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice.
Journal of Biological Chemistry
280:
29946–29955.
|
|
|
Romano M and
Serhan CN
(1992)
Lipoxin generation by permeabilized human platelets.
Biochemistry
31:
8269–8277.
|
|
|
Samuelsson B,
Dahlén S,
Lindgren JA,
Rouzer CA and
Serhan CN
(1987)
Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.
Science
237:
1171–1176.
|
|
|
Sardesai VM
(1992)
Biochemical and nutritional aspects of eicosanoids.
Journal of Nutritional Biochemistry
3:
562–572.
|
|
|
Schaloske RH and
Dennis EA
(2006)
The phospholipase A2 superfamily and its group numbering system.
Biochimica et Biophysica Acta
1761:
1246–1259.
|
|
|
Serhan C
(2007)
Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.
Annual Review of Immunology
25:
101–137.
|
|
|
Silva AR,
Pacheco P,
Viera-de-Abreu A et al.
(2009)
Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon.
Biochimica et Biophysica Acta
1791:
1066–1075.
|
|
|
Smart BP,
Pan YH,
Weeks AK et al.
(2004)
Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structured-guided study.
Bioorganic Medicinal Chemistry
12:
1737–1749.
|
|
|
Sobrado M,
Pereira MP,
Ballesteros I et al.
(2009)
Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPAR gamma dependent, neuroprotective effects of rosiglitazone in experimental stroke.
Journal of Neuroscience
29:
3875–3884.
|
|
|
Spector AA
(2009)
Arachidonic acid cytochrome P450 epoxygenase pathway.
Journal of Lipid Research
50:
S52–S56.
|
|
|
Tanioka T,
Nakatani Y,
Semmyo N,
Murakami M and
Kudo I
(2000)
Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis.
Journal of Biological Chemistry
275:
32775–32782.
|
|
|
Ulrich V,
Zou M-H and
Bachschmid M
(2001)
New physiological and pathophysiological aspects on the thromboxane A2–prostacyclin regulatory system.
Biochimica et Biophysica Acta
1532:
1–14.
|
|
|
Yang S,
Wei S,
Pozzi A and
Capdevila JH
(2009)
The arachidonic acid epoxygenase is a component of the signaling mechanisms for VEGF-stimulated angiogenesis.
Archives of Biochemistry and Biophysics
489:
82–91.
|
|
|
Yeh H-C,
Tsai A-L and
Wang L-H
(2007)
Reaction mechanisms of 15-hydroxyperoxyeicosa tetraenoic acid catalyzed by human prostacyclin and thromboxane synthase.
Archives of Biochemistry and Biophysics
461:
159–168.
|
|
|
Yu BZ,
Rogers J,
Nicol G et al.
(1998)
Catalytic significance of the specificity of divalent cations as KS* and k*cat cofactor for secreted phospholipase A2.
Biochemistry
37:
12576–12587.
|
|
|
Zarini S,
Gijón MA,
Ransome AE,
Murphy RC and
Sala A
(2009)
Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation.
Proceedings of the National Academy of Sciences of the USA
106:
8296–8301.
|
|
|
Zhou L and
Nillsson Å
(2001)
Sources of eicosanoid precursor fatty acid pools in tissues.
Journal of Lipid Research
42:
1521–1542.
|
|
|
Zhou L,
Vessby B and
Nillsson Å
(2002)
Quantitative role of plasma free fatty acids in the supply of arachidonic acid to extrahepatic tissues in rats.
Journal of Nutrition
132:
2626–2631.
|
| Further Reading |
|
|
Baker RR
(1990)
The eicosanoids: a historical overview.
Clinical Biochemistry
23:
455–458.
|
|
|
Sigal E
(1991)
The molecular biology of mammalian arachidonic acid metabolism.
American Journal of Physiology
260:
L13–L28.
|
|
|
book
Smith WL and
Murphy RC
(2002)
"The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathway".
In: Vance DE and
Vance J E (eds)
Biochemistry of Lipids, Lipoproteins and Membranes,
4th edn,
pp. 341–371.
Amsterdam: Elsevier Science.
|
